Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TNYA |
---|---|---|
09:32 ET | 5733 | 4 |
09:34 ET | 5217 | 3.913 |
09:36 ET | 9354 | 3.865 |
09:38 ET | 8330 | 3.965 |
09:39 ET | 5194 | 3.9 |
09:41 ET | 1896 | 3.8948 |
09:43 ET | 400 | 3.8829 |
09:45 ET | 2190 | 3.905 |
09:48 ET | 386 | 3.94 |
09:50 ET | 300 | 3.92 |
09:52 ET | 2425 | 3.8932 |
09:54 ET | 3300 | 3.925 |
09:56 ET | 452 | 3.94 |
09:57 ET | 300 | 3.93 |
09:59 ET | 2577 | 3.93 |
10:01 ET | 3404 | 3.9689 |
10:03 ET | 1300 | 3.98 |
10:06 ET | 1550 | 3.9955 |
10:08 ET | 3837 | 3.96 |
10:10 ET | 2060 | 3.9395 |
10:12 ET | 800 | 3.97 |
10:14 ET | 100 | 3.96 |
10:19 ET | 100 | 3.96 |
10:21 ET | 490 | 3.94 |
10:24 ET | 300 | 3.96 |
10:26 ET | 149 | 3.97 |
10:28 ET | 200 | 3.975 |
10:30 ET | 6787 | 3.9501 |
10:32 ET | 766 | 3.91 |
10:33 ET | 800 | 3.9 |
10:37 ET | 1445 | 3.85 |
10:39 ET | 8672 | 3.87 |
10:42 ET | 1800 | 3.92 |
10:44 ET | 400 | 3.92 |
10:46 ET | 506 | 3.91 |
10:48 ET | 1600 | 3.91 |
10:50 ET | 3250 | 3.8432 |
10:51 ET | 10335 | 3.825 |
10:53 ET | 1200 | 3.8099 |
10:55 ET | 400 | 3.8 |
10:57 ET | 2800 | 3.81 |
11:00 ET | 1200 | 3.83 |
11:02 ET | 3333 | 3.7901 |
11:04 ET | 3100 | 3.775 |
11:06 ET | 1998 | 3.7601 |
11:08 ET | 33047 | 3.72 |
11:09 ET | 470 | 3.75 |
11:11 ET | 400 | 3.7 |
11:13 ET | 5289 | 3.67 |
11:15 ET | 2726 | 3.62 |
11:18 ET | 600 | 3.62 |
11:20 ET | 700 | 3.58 |
11:22 ET | 300 | 3.62 |
11:24 ET | 4890 | 3.675 |
11:26 ET | 1604 | 3.68 |
11:27 ET | 1300 | 3.7 |
11:29 ET | 399 | 3.73 |
11:31 ET | 718 | 3.7397 |
11:33 ET | 206 | 3.73 |
11:36 ET | 578 | 3.7564 |
11:38 ET | 1420 | 3.765 |
11:40 ET | 500 | 3.7898 |
11:42 ET | 9940 | 3.72 |
11:44 ET | 682 | 3.73 |
11:45 ET | 691 | 3.73 |
11:47 ET | 1174 | 3.77 |
11:54 ET | 500 | 3.76 |
11:56 ET | 300 | 3.76 |
12:00 ET | 400 | 3.78 |
12:05 ET | 259 | 3.79 |
12:09 ET | 345 | 3.8 |
12:12 ET | 400 | 3.805 |
12:14 ET | 500 | 3.78 |
12:20 ET | 2136 | 3.7901 |
12:21 ET | 300 | 3.8 |
12:23 ET | 695 | 3.795 |
12:25 ET | 544 | 3.81 |
12:27 ET | 100 | 3.81 |
12:30 ET | 550 | 3.82 |
12:36 ET | 200 | 3.81 |
12:38 ET | 100 | 3.83 |
12:39 ET | 100 | 3.83 |
12:43 ET | 200 | 3.83 |
12:50 ET | 210 | 3.8499 |
12:52 ET | 100 | 3.84 |
12:54 ET | 100 | 3.84 |
12:57 ET | 100 | 3.83 |
12:59 ET | 100 | 3.83 |
01:03 ET | 518 | 3.82 |
01:06 ET | 1000 | 3.8299 |
01:10 ET | 137 | 3.8209 |
01:12 ET | 400 | 3.82 |
01:14 ET | 300 | 3.82 |
01:15 ET | 119 | 3.8291 |
01:21 ET | 100 | 3.83 |
01:26 ET | 100 | 3.83 |
01:28 ET | 100 | 3.84 |
01:33 ET | 100 | 3.84 |
01:35 ET | 300 | 3.83 |
01:39 ET | 400 | 3.805 |
01:42 ET | 457 | 3.81 |
01:46 ET | 300 | 3.84 |
01:48 ET | 459 | 3.8599 |
02:02 ET | 200 | 3.84 |
02:04 ET | 100 | 3.85 |
02:06 ET | 200 | 3.85 |
02:08 ET | 990 | 3.8407 |
02:15 ET | 100 | 3.85 |
02:18 ET | 200 | 3.85 |
02:20 ET | 100 | 3.85 |
02:29 ET | 100 | 3.84 |
02:33 ET | 300 | 3.83 |
02:36 ET | 2200 | 3.8499 |
02:42 ET | 400 | 3.84 |
02:51 ET | 757 | 3.8495 |
02:56 ET | 500 | 3.84 |
02:58 ET | 100 | 3.84 |
03:02 ET | 200 | 3.84 |
03:05 ET | 1313 | 3.82 |
03:09 ET | 450 | 3.81 |
03:12 ET | 500 | 3.81 |
03:14 ET | 766 | 3.83 |
03:16 ET | 700 | 3.83 |
03:18 ET | 100 | 3.82 |
03:23 ET | 100 | 3.82 |
03:30 ET | 100 | 3.825 |
03:36 ET | 1536 | 3.81 |
03:38 ET | 700 | 3.83 |
03:39 ET | 400 | 3.83 |
03:43 ET | 2928 | 3.86 |
03:48 ET | 865 | 3.86 |
03:50 ET | 100 | 3.86 |
03:52 ET | 852 | 3.87 |
03:56 ET | 1900 | 3.85 |
03:57 ET | 2278 | 3.86005 |
03:59 ET | 35915 | 3.88 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Tenaya Therapeutics Inc | 313.3M | -2.4x | --- |
Zentalis Pharmaceuticals Inc | 309.6M | -1.3x | --- |
ALX Oncology Holdings Inc | 317.8M | -1.6x | --- |
Omeros Corp | 305.9M | -1.8x | --- |
Cabaletta Bio Inc | 325.9M | -4.2x | --- |
Atea Pharmaceuticals Inc | 328.5M | -2.0x | --- |
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $313.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 78.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.65 |
Book Value | $2.04 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.